Novo Nordisk, a pharmaceutical company specializing in diabetes and obesity medications, has announced a price adjustment for its weight loss drugs, Wegovy and Ozempic. The company is lowering the price of these medications to $349 per month, a reduction from their previous rates. This decision follows recent negotiations with Eli Lilly, aimed at streamlining the distribution of these drugs within the United States. The company cited increased market demand and operational efficiencies as contributing factors to the price decrease. The adjustment is expected to impact patients and healthcare providers.
Credits: US Top News and Analysis
